Nerve growth factor (NGF) is a potent mediator of inflammatory hyperalgesia, in addition to roles in the development and maintenance of neurons. We provide evidence for the novel concept that microvascular endothelial cells play a critical primary role in NGF-mediated events that lead to inflammatory hyperalgesia in rat skin. We show that, surprisingly, neutrophils are not directly activated by NGF, although local administration of NGF mediates thermal hyperalgesia via mechanisms involving concomitant neutrophil accumulation. The co-administration of actinomycin D with NGF negated both neutrophil accumulation and thermal hyperalgesia, indicating the dependence of NGF on local de novo protein synthesis. More significantly, an antibody against the endothelial-derived adhesion molecule ICAM-1 also blocked neutrophil accumulation and thermal hyperalgesia. Finally the ability of NGF to stimulate ICAM-1 in human cultured umbilical vein endothelial cells is shown. We propose that NGF acts primarily to activate endothelial cells and that this response is essential for the ensuing neutrophil accumulation and hyperalgesia. The findings reveal a central role of the endothelial cell in initiating NGF-dependent inflammatory hyperalgesia and emphasize the importance of further investigations aimed at examining the feasibility of new therapeutic strategies that target NGF.
its production from cells is stimulated by cytokines that include tumor necrosis factor α (TNF-α) and interleukin-1 (IL-1; 8, 9). NGF is considered to act primarily via its high-affinity tyrosine kinase receptor TrkA, but the less-selective, low-affinity p75 receptor is now considered to play a role in mediating NGF-induced effects (10) . The intimate relationship of NGF with sensory neurons has prompted the suggestion that NGF mediates its hyperalgesic effects via sensory neurons, or the neuropeptides that they release. Indeed it is well-established that NGF upregulates sensory neuropeptide synthesis and release at the ganglia level (11, 12) and facilitates capsaicin responses via the vanilloid VR1 receptor. However, there is less evidence to suggest that the best-characterized neuropeptide, substance P, is involved in the hyperalgesic response to NGF (13) , although a substance P neurokinin-1 (NK 1 ) receptor antagonist has been shown to antagonise NGF-induced airway hyperresponsiveness in the airways (14) .
Despite the substantial knowledge of the pro-inflammatory potential of NGF, there is a lack of knowledge of its precise activity, although many individual observations have been made that cover most inflammatory cells, (15) . This contrasts with the substantial studies and reviews that have examined the hyperalgesic activity of NGF (16, 17) . NGF induces a long-lasting inflammatory hyperalgesia after its systemic administration, which appears to involve central, in addition to peripheral, mechanisms (18, 19) . More specifically, the administration of picomolar amounts of NGF locally into skin or paw produces a sustained (3-5 h) thermal hyperalgesia in rodents that can last for a number of hours as observed by the measurement of both mechanical and thermal hyperalgesia in rodents (20, 21) . The initial phases of NGF-induced hyperalgesia have been shown to involve sympathetic neurons (21) and mast cells (22, 23) . We have shown that the more sustained thermal hyperalgesia is dependent on the presence of neutrophils, as it is not observed when circulating neutrophils are removed by use of a selective antibody (24) . The neutrophil accumulation occurs from 1 h after NGF administration and appears to be critical to the associated appearance of macrophages and lymphocytes at the inflammatory site, after intradermal injection of NGF (25) . These findings have led us to suggest that neutrophils play an essential role in initiating and mediating NGF responses (25) . Interestingly, NGF extracted from mouse salivary glands has been shown to be chemotactic for rodent neutrophils both in vivo and in vitro (26, 27) . The arachidonate 5-lipoxygenase product leukotriene B 4 (LTB 4 , known to be released from activated neutrophils) has been suggested to be involved in NGF-induced thermal hyperalgesia as 5-lipoxgenase inhibitors attenuate NGF-induced thermal hyperalgesia and LTB 4 levels are increased in NGF-treated skin (24, 28) .
The aim of this study was to learn more about the precise mechanisms by which NGF exerts its effects. We show that, contrary to our initial hypothesis, NGF does not appear to directly activate rat neutrophils. We present evidence that the neutrophil accumulation in the rat that is central to NGF-induced thermal hyperalgesia is secondary to an up-regulation of endothelial cell adhesion molecule (ICAM) that occurs following NGF administration in the rat. This is, to our knowledge, the first evidence to show that endothelial cells play an essential role in the induction of thermal hyperalgesia.
MATERIALS AND METHODS

Measurement of thermal hyperalgesia
Male Wistar rats (70-100 g) and Sv129+C57BL/6 mice either male wild-type (+/+, 25-30 g) or male tachykinin NK 1 receptor knockouts (−/−) were used. All procedures were in accordance with U.K. Home Office regulations. The hind paw thermal nociceptive thresholds were determined before and after administration of test agents according to the method of Hargreaves et al. (29) and Bennett et al. (24) . Test agents (in 100 µl for rat and 25 µl for mouse) were injected via the intraplantar (i.pl.) route into one hind paw, the other serving as an uninjected control. Injections were performed under either isofluorane or halothane (2%) anesthesia. Briefly, the rodent was housed in a behavioral box on a raised glass platform, at room temperature, for each reading. Measurement of nociceptive threshold was made with an automatic heat source, which shone through the glass platform onto the plantar surface of the paw. The heat source emitted a heat ~10°C higher than room temperature and consisted of a light bulb (50 W, 10 V) and a timer linked to a light sensor. Withdrawal of the paw produced a change in the measured light and stopped the timer and heat source. Measurements were taken in triplicate and the mean value was taken as the nociceptive threshold.
Nociceptive thresholds were measured in both paws 15 min prior to i.pl. injection (termed the basal reading) and at 30, 90, 180, 270 min after i.pl. injection of 7S murine NGF (TCS Biologicals, Oxford, U.K.), LTB 4 (Calbiochem Biochemicals, Nottingham, U.K.), 5-HETE or carrageenan (both Sigma Chemicals, Poole, U.K.), or vehicle control. The injection plan was unknown to the investigator. Results, measured as paw withdrawal latency, are expressed as difference from uninjected contralateral paw. Animals were killed, on completion of the experiment, by CO 2 overdose and cervical dislocation.
Measurement of neutrophil accumulation
Rats (230-300 g) were anesthetized by intraperitoneal (i.p.) injection of sodium pentobarbitone (Sagatal 60 mg/kg) and mice (25-30 g ) with isofluorane (2%; 2% O 2 ). The larger rat was used for neutrophil accumulation studies, as compared with that used in hyperalgesia studies, for ethical reasons. This allowed more dorsal skin sites to be available for assay, facilitating better experimental design. It has previously been shown that NGF stimulates a similar neutrophil accumulation in both paw and rat skin of large versus small rats (24) . Dorsal skin was shaved and marked out for intradermal (i.d.) injections. Animals were allowed to recover from anesthetic and, after a 5 h accumulation period, they were killed by an anesthetic overdose. The dorsal skin was then removed and the skin sites punched out (16-mm diameter for rat and 8-mm diameter for mouse). Skin sites were frozen at -20°C until assay for myeloperoxidase (MPO) levels in order to assess the neutrophil accumulation in the rat skin.
MPO activity was used as an index of neutrophil accumulation as determined by measuring the H 2 O 2 -dependent oxidation of tetramethylbenzidine (TMB). Values were calculated from purified leukocyte MPO standards as previously detailed (30) (31) (32) . The frozen skin samples were pulverized and then homogenized (Polytron, Brinkman, NY) in 47 mM phosphate buffer (pH 6.0) containing 0.5% hexadecyl trimethylammonium bromide (HTAB). Homogenates were centrifuged at 13,000 g for 10 min. The supernatant was stored at -80°C until assay. The duplicate samples were diluted 1:2 with 50 mM phosphate buffer (pH 6.0) containing 0.5% HTAB and then (25 µl) incubated with 0.1 ml of "K-Blue" substrate (stabilized H 2 O 2 and TMB). The plate was shaken for 5 s, and absorbance was measured at 620 nm (using Anthos HTIII Labtech International, East Sussex, U.K.). MPO activity was expressed as neutrophils/site.
Drug treatment protocols
Pre-treatment of anti-rat ICAM-1 monoclonal antibody (mAb, 2 mg/kg, Serotec, Oxford, U.K.), irrelevant, anti-human PECAM-1 monoclonal antibody (2 mg/kg, Serotec) or saline (200 µl) was injected i.v. into the tail vein 30 min prior to i.pl. injection. Neutrophil depletion was performed by administration of a rabbit anti-rat neutrophil antiserum (2 ml/kg, i.p., Accurate Chemicals, Westbury, NY), 18 h prior to start of the experiment. Additional groups of animals received saline i.p. or appropriate irrelevant rabbit anti-ovalbumin antiserum (2 ml/kg i.p.), 18 h prior to beginning of the experiment in order to act as the vehicle control. A 2 ml blood sample was taken by cardiac puncture to determine cell counts, just before the termination of the experiment. The rabbit anti-rat neutrophil anti-serum produced a complete and selective depletion of circulating neutrophils in the blood of rats as previously observed (see, 24). Differential leukocyte counts revealed a lack of circulating neutrophils, while similar percentages of total leukocyte counts were observed in saline and irrelevant antibody-treated rats (20.4 ± 2.7% and 16.9 ± 2.1%, respectively, mean ± SE, n=4, data expressed as percentage of total leukocytes). Actinomycin D (1 µmol i.pl. or i.d., Sigma Chemicals) was given as a co-treatment with either vehicle or NGF.
Cell culture, preparation, and FACS analysis
Human umbilical vein endothelial cells (HUVECs) were purchased from BioWhittaker (Berks, U.K.) and grown in endothelial growth medium (EGM-II, BioWhittaker) in sixwell plates (Falcon, Herts, U.K.) at a concentration of 1 × 10 5 cells in a humidified atmosphere of 95% O 2 , 5% CO 2 . HUVECs were always used at the third growth passage. Confluent cells were then treated with NGF (40 pmol in 500 µl EGM-II for 5 h). Control cells were treated with EGM-II (500 µl). Cells were then washed in 2 ml Hank's buffered saline solution (HBSS) for 1 min. A FITC-conjugated mouse anti-human monoclonal antibody against ICAM-1 (Serotec) was diluted to 4 µg/ml with EGM-II containing 0.1% bovine serum albumin. This was then added to the control and treated cells (500 µl) and incubated in the dark at 37°C for 30 min. HUVEC dissociation was performed by treating HUVEC cells with trypsin/EDTA (500 µl/well) at 37°C for 2 min. Trypsin activity was blocked by the addition of 500 µl of trypsin neutralizing solution (TNS, Biowhittaker). Flow cytometry, conducted on a FACsCaliberTM and analyzed by using CELLQuest software (Becton Dickinson, Oxford, U.K.), was then performed on the cells collected.
Preparation and measurement of neutrophil activation
Mixed peritoneal leukocytes were elicited from 220-250 g male Wistar rats by an intraperitoneal injection of 10 ml of a solution of 6% glycogen in sterile saline. After ~20 h, the rats were killed with a CO 2 overdose followed by cervical dislocation and the peritoneal cells were harvested.
The peritoneal fluid was centrifuged at 4°C, for 10 min at 400 g. After centrifugation, the supernatant was discarded and the pelleted cells were resuspended in a small volume of modified HBSS. Once total cell count was determined, the cells were resuspended in complete HBSS (containing 1.26 mM Ca 2+ and 0.41 mM Mg
2+
) at 5 × 10 6 cells/ml. The percentage of neutrophils in the resuspended sample was >75% neutrophils (33) .
Aliquots of 0.5 ml or 1.0 ml mixed peritoneal leukocytes at 5 × 10 6 cells/ml were placed in 1.5 ml HBSS for 10 min at 37°C with the drug of interest, added in 5 µl, or its vehicle (saline). After this preincubation, 2 µM of Ca 2+ -ionophore A23187 (dissolved in DMSO, used as a positive control) or the test agents NGF (100 PM, 1 nM and 10 nM) was added to the aliquots and incubated for a further 30 min or 4 h at 37°C. After these time periods the cells were then pelleted and the supernatants were decanted and frozen at -20°C.
Measurement of leukocyte eicosanoid production (LTB 4 and TxB 2 ) by radioimmunoassay
LTB 4 and TxB 2 levels in supernatants were measured by direct radioimmunoassay (RIA) of supernatant. Reagents were from Sigma Chemicals, unless stated. This was performed by taking 10 µl (for TxB 2 ) and 5 µl (for LTB 4 ) aliquots of the thawed neutrophil supernatants into a total of 100 µl RIA buffer. The appropriate polyclonal antibody, anti-LTB 4 and anti-TxB 2 , prepared from rabbits (final dilution 1:2000) was added (200 µl) together with 100 µl (0.01 µCi) [H 3 ] -TxB 2 or -LTB 4 (Amersham International, Bucks, U.K.). These samples were then incubated for 18 h at 4°C to allow binding. After this time, bound label was separated from unbound free label by mixing the samples with 200 µl dextran-coated charcoal, then centrifuged at 4°C for 10 min at 800 g to remove the charcoal, after a 15-min incubation at 4°C. The bound label antibody (Ab) complexes were decanted into vials to which 5 ml liquid scintillant (0.4% 2,5-diphenyloxazole in 1.5 l toluene/0.9 l ethoxyethanol) was added, and then samples were counted in a Packard LS 800 liquid scintillation β spectrometer for 5 min a sample. Samples values were obtained by extrapolation from a standard curve constructed by using authentic LTB 4 or TxB 2 (3.125-5000 pg/tube, Calbiochem Biochemicals, Poole, UK).
Immunohistochemistry detection of ICAM-1 on rat dorsal skin in response to NGF by indirect peroxidase method
Skin samples (two slices, 8 mm diameter each) injected with NGF (40 pmol/site) or Tyrode vehicle 5 h before collection, were immediately embedded in OCT-compound and frozen in liquid nitrogen. Using a cryostat (model OTF, Bright), the tissue blocks were cut into sections of 8-10 µm, mounted on 3-aminopropyltriethoxysilane (APES, Sigma Chemicals)-coated slides, and subsequently numbered. The slides were stored at -80°C until further use. Immunohistochemical localization of ICAM-1 was assessed by using the mouse anti-rat ICAM-1 monoclonal primary antibody (from Serotec) via the indirect peroxidase method. The sections were incubated with ICAM-1 antibody (10 and 30 µg/ml) or control mouse immunoglobulin (Sigma Chemicals) at the same concentration for 90 min in a humidity box at 21°C. This was followed by treatment of the sections with H 2 O 2 (1%, 10 min) to block endogenous peroxidase. After washing with PBS, the sections were incubated with the conjugated (HRP) rat anti-mouse IgG 1 heavy chain monoclonal secondary antibody (dilution 1:30, Serotec) for 30 min. Following washing with PBS, a solution containing diaminobenzidine (DAB 0.75 mg/ml, 1:10) and H 2 O 2 (0.015%) in PBS was then placed on the sections and incubated for 15 min. The slides were stained with hematoxylin, dehydrated, cleansed, mounted with a coverslip, and viewed. Small blood vessels were identified by this morphology.
Statistics
Results are presented as mean ± SE and analyzed statistically by ANOVA followed by Bonferroni's modified t-test. The n value indicates the number of animals (i.e., samples from those animals) used for in vivo and in vitro experiments in each case.
RESULTS
NGF induces thermal hyperalgesia after intraplantar injection into the rat, as shown in Fig. 1a . The average time (s) for paw withdrawal for the contralateral uninjected paw is 11.5 ± 1.0 s, compared with 6.2 ± 0.8 s, mean ± SE, n=8 for the NGF-treated paw by the fifth hour. There was no significant difference in the results obtained for contalateral paws over either the 5 h treatment period, or in rats treated with different agents. The effect of the established inflammatory stimulus carrageenan is also shown in Fig. 1a . Figure 1b confirms previous evidence (24) that thermal hyperalgesia is dependent on neutrophil accumulation, as thermal hyperalgesia was not observed in rats treated with an anti-neutrophil antiserum to block circulating neutrophils. The observation that 5-lipoxygenase inhibitors blocked NGF-induced hyperalgesia compliments results shown in Fig. 1c and 1d where the comparative ability of the 5-lipoxygenase products LTB 4 and 5-HETE to mediate thermal hyperalgesia in the rat paw is shown.
The thermal hyperalgesia response to NGF is also observed in the mouse as shown in Fig. 2a . The average time (s) for paw withdrawal for the contralateral uninjected paw is 10.1 ± 1.0 s compared with 5.9 ± 0.7 s, mean ± SE, n=6 for the NGF-treated paw at 5 h in the wild-type mice. Similar average time (s) for paw withdrawal for the contralateral uninjected paw of 9.6 ± 0.9 s compared with 5.4 ± 0.9 s, mean ± SE, n=6 for the NGF-treated paw at 5 h in the NK 1 knockout mouse were measured. Thus no differences between wild-type and NK 1 knockout mice were observed. The administration of NGF was associated with neutrophil accumulation as shown in Fig. 2b . However, the results reveal similar responses in both the wild-type and tachykinin NK 1 receptor knockout mice. This finding suggests that the neutrophil accumulation, in addition to the thermal hyperalgesia, induced by NGF, is independent of the involvement of the NK 1 receptor. The NK 1 receptor knockout mice are devoid of the normal NK 1 -mediated plasma extravasation observed in response to capsaicin-mediated sensory neuron activation and the neutrophil accumulation mediated by carrageenan that is partly dependent on the NK 1 receptor. (32) . Thus, it is concluded at this stage that NGF mediates thermal hyperalgesia via a mechanism that is independent of the neurogenic NK 1 receptor, but dependent on the presence of neutrophils and the arachidonate 5-lipoxygenase pathway.
The well-established ability of neutrophils to release 5-lipoxygenase products led us to investigate the activity of rat isolated neutrophils in vitro. The neutrophils were incubated in vitro for either 30 min or 4 h with either calcium ionophore or NGF. Fig. 3 shows that, under these circumstances, the calcium ionophore released significant amounts of immunoreactive LTB 4 and myeloperoxidase. TxB 2 levels were also measured, for use as an alternative marker of eicosanoid production from activated neutrophils. NGF was not able to stimulate release of any agent. Overall, there are no significant differences in LTB 4 , TxB 2 , and MPO levels measured in supernatants from these two time points. The lack of ability of NGF to stimulate either eicosanoid or MPO release in vitro led us to conclude that NGF cannot directly act to stimulate neutrophils.
Neutrophil accumulation induced by NGF in rat skin was increased in a time-dependent manner over 0-5 h (24, 25) in keeping with the time course of neutrophil accumulation that is observed secondary to the up-regulation of endothelial cell adhesion molecules (34) . Thus, the effect of actinomycin D, an mRNA transcription inhibitor, was investigated on NGF-induced neutrophil accumulation. Actinomycin D blocked NGF-induced neutrophil accumulation (Fig. 4a) and NGF-induced thermal hyperalgesia was abolished by actinomycin D (Fig. 4b) . In further experiments the involvement of an endothelial cell adhesion molecule that is known to be upregulated in response to cytokines (ICAM-1) was investigated by use of a selective antibody. Pre-treatment (i.v.) of anti-ICAM-1 mAb (2 mg/kg) 15 min before administration of NGF significantly reduced the neutrophil accumulation (see Fig. 5a ), while pre-treatment with an irrelevant antibody (2 mg/kg) did not compromise the neutrophil accumulation. A similar pretreatment with anti-ICAM-1 mAb abolished NGF-induced thermal hyperalgesia (Fig. 5b) ; with NGF producing similar hyperalgesia in the presence of irrelevant antibody. An up-regulation of ICAM-1 in the rat cutaneous microvasculature, as determined by immunohistochemical analysis, is observed at 5 h after injection of NGF (40 pmol) into the skin site (see Fig. 6b ).
To ascertain whether NGF was influencing the increased expression of ICAM-1 (labeled with a FITC-conjugated ICAM-1 mAb), FACS analysis was conducted on HUVECs in culture treated with NGF (40 pmol) for 5 h. Expression of ICAM-1 was increased significantly (see Fig. 7 ). Vehicle-treated cells did not demonstrate any increased ICAM-1 expression.
DISCUSSION
The results confirm that NGF induces thermal hyperalgesia that is secondary to neutrophil accumulation in the rat (24) . In addition, the arachidonate lipoxygenase products LTB 4 and 5-HETE were also shown to mediate thermal hyperalgesia, although the effect of 5-HETE was transient when compared with LTB 4 , confirming previous suggestions that 5-lipoxygenase products can induce nociceptor activation (35, 36) . A similar thermal hyperalgesic and neutrophil accumulation response to NGF was observed in the mouse, where the deletion of the tachykinin NK 1 receptor was without effect on the response, thus providing evidence for lack of involvement of substance P and its major receptor in either the neutrophil accumulation or the thermal hyperalgesia. The obvious conclusion from our results at this point was that NGF acts independently of substance P to stimulate neutrophil accumulation and that the neutrophils then emigrate into skin, where they are activated to release LTB 4 . However, NGF totally failed to activate rat isolated neutrophils in vitro and is thus unlikely to be the sole mediator involved in the release of LTB 4 release in vivo. By comparison, results of subsequent experiments with the protein synthetase/mRNA inhibitor actinomycin D in vivo provided evidence that NGF stimulates de novo protein synthesis-dependent up-regulation of endothelial adhesion molecule expression, which in turn leads to neutrophil accumulation and emigration into extravascular tissues. The effect of NGF was shown to be blocked by pre-treatment with a monoclonal antibody to ICAM-1, but not an irrelevant antibody, used as control. Thus, these results provide novel evidence that NGF acts primarily to activate endothelial cells to mediate inflammatory cell accumulation and thermal hyperalgesia. The source of the 5-lipoxygenase products remains unclear as does the possible candidates that are responsible for stimulating LTB 4 release. Our recent histochemical study (25) has revealed that NGF induced a dermal infliltrate of macrophages, which was observed only when neutrophils were present (i.e., not observed when neutrophils were depleted). Therefore, it is possible that co-operativeness between the neutrophil and macrophages leads to the LTB 4 production from either the macrophage or the neutrophil by as-yet-unidentified mechanisms. However, the arachidonate lipoxygensase products, once released, may well have a direct effect on sensory neurons that mediate the hyperalgesia, as it has been shown that they can act as agonists at the vanilloid VR1 receptor on sensory neurons in culture (36) .
NGF has been shown to stimulate polymorphonuclear leukocyte chemotaxis (37) . It was suggested that this was a consequence of protease activity, in that blocking an essential histidine amino acid led to a loss of the NGF-induced chemotactic ability. In the same year, Boyle and coworkers demonstrated that NGF extracted from mouse submandibular gland acted via a complement-independent pathway to promote polymorphonuclear leukocyte accumulation in mouse skin in vivo and correlated this to their earlier observation of the wound-healing activity of NGF in the presence of plasma (38) . However, our results show that NGF does not directly stimulate neutrophils. This may be directly related to the fact that the murine 7S recombinant NGF, used in this study, may not possess some of the factors that NGF purified from saliva, used in previous studies, contains. Alternatively, our results may be related to a lack of functional TrkA receptors on polymorphonuclear leukocytes. There is little evidence, to our knowledge, of TrkA receptors on the neutrophil. One study has suggested a presence of TrkA receptors on neutrophils as NGF and TrkA mRNA were located with polymorphonuclear-like cells of the lamina propria invading the inflammatory wall, in human inflamed intestine of patients with inflammatory bowel disease (39). However, it is possible that these polymorphonuclear cells may be intimately linked with endothelial cells that are now known to possess TrkA receptors (see below). In a separate study of injured tooth pulp in the rat, Woodnutt et al. (40) demonstrated that TrkA immunoreactivity was present in invading polymorphonuclear leukocytes, although only one of the two TrkA antibodies used detected immunoreactive TrkA. It was shown that this antibody detected the intracellular domain of TrkA only and that the second antibody, selective for the extracellular domain of TrkA, could not detect any trkA on polymorphonuclear leukocytes (40) . Thus, there is far from conclusive evidence to suggest that neutrophils possess the NGF receptors necessary to activate neutrophils. Interestingly, there is evidence that NGF can influence polymorphonuclear leukocyte neutrophil activity. NGF is known to suppress apoptosis of murine neutrophils cultured for 9 h in vitro (41, 42) and also to promote superoxide production induced by phorbol 12-myristate 13-acetate (PMA) and opsonized zymosan. The latter findings support those of Gruber and colleagues (43) .
Knowledge that relates to the emigration of neutrophils from the blood to the extravascular tissue has expanded greatly since it was realized that there were two main mechanisms through which neutrophils emigrate, namely after direct stimulation of neutrophil receptors by chemotactic mediators; for example, C5a (44) and after activation of endothelial molecules by cytokines, such as IL-1 and TNF-α (45) . Leukocyte migration occurs via a process involving multiple steps, depending on the adhesive proteins and their respective ligands that are selectively activated, on the leukocytes and endothelial cells (46) . Neutrophil emigration that occurs as a consequence of chemotactic mediators is quicker in onset (occurs within 30 min) than that which occurs secondary to endothelial activation (occurs over hours) as observed in rabbit skin (34) . Furthermore, these authors also demonstrated that neutrophil accumulation induced by IL-l was dependent on de novo protein synthesis, whereas that mediated by chemotactic mediators was not. It has been more recently shown by using human cultured endothelial cells that, although an antibody to ICAM-1 could significantly inhibit IL-1-induced neutrophil accumulation, it had little effect when administered alone on neutrophil accumulation induced by chemotactic mediators (47) . We were aware from our previous studies that significant neutrophil accumulation into rat skin did not occur until 1-3 h after NGF injection (24) . The experiments that we have now performed are in keeping with the hypothesis that NGF is initially acting to stimulate endothelial cell adhesion molecules that include ICAM-1 in that actinomycin D blocked neutrophil accumulation. The influence of NGF on endothelial cell biology has been neglected until recently. However, a pivotal study by Raychaudhuri and co-workers (48) has demonstrated a clear link between NGF and the up-regulation of ICAM-1 expression in human dermal cultured microvascular endothelial cells, which correlated with an ability of the NGFstimulated endothelial cells to mediate leukocyte adhesion (48) . The amount of NGF used to stimulate ICAM-1 expression in culture were of the same order as the doses that stimulated neutrophil accumulation and thermal hyperalgesia in vivo in this study. Furthermore, RT-PCR and immunological methods have demonstrated that human cultured umbilical vein endothelial cells express TrkA NGFR and p75 NTR , thus clear evidence for the presence of NGF receptors on endothelial cells exists. These authors have also demonstrated an angiogenic role of NGF that may be relevant to inflammation.
In conclusion, these results identify a central role of the post-capillary venule endothelial cell in initiating thermal hyperalgesia induced by NGF in the rat. The results highlight that the neutrophils accumulate in response to NGF via an endothelial-dependent step involving the major adhesion molecule ICAM-1. The functional extent of the consequences of the ability of NGF to stimulate endothelial cell adhesion molecule expression is at present unclear, although we have shown previously that macrophage and lymphocyte numbers increase at NGF pretreated sites (25) . The evidence supports the concept that therapeutic interventions that block inappropriate NGF generation may play vital roles in the treatment of inflammatory disease and the associated pain. 
